As a specialized eCTD service provider, BrilliantMed has achieved a landmark innovation in the pharmaceutical sector. We successfully supported a prestigious Fortune 500 pharmaceutical company in submitting a global new drug registration dossier in eCTD (electronic Common Technical Document) format to China’s Center for Drug Evaluation (CDE). Remarkably, this submission was completed two days earlier than the corresponding filing in the United States. This accomplishment marks a significant milestone in BrilliantMed’s growth and signals a promising new chapter for the internationalization of China’s pharmaceutical industry.
1. Breaking Industry Norms: Leading the Shift from “Follower” to “Pioneer” in Submission Timing
Historically, there has been an implicit delay between U.S. and China new drug filings—industry practice treats submissions as “simultaneous,” but China’s filing typically occurs up to a month after the U.S. BrilliantMed’s achievement of “China-first submission” breaks this long-standing convention. This success rests on the seamless coordination of three key strengths: rigorous project management, close collaboration with the client team, and flawless teamwork with the publishing department.
2. Overcoming Technical Challenges: Navigating China’s Unique eCTD Requirements
It’s widely recognized that China’s eCTD filing presents greater complexity than the U.S., due to its bilingual documentation requirements, which significantly increase the workload and complexity of document processing. Additionally, the mandatory full Chinese-language hyperlinking of registration materials and extra electronic signature procedures impose higher technical demands. Leveraging deep expertise and extensive hands-on experience, BrilliantMed’s team successfully tackled these challenges, ensuring accuracy and completeness throughout the submission.
3. Robust Team Support: The Driving Force Behind Project Success
We know that exceptional project management and a highly skilled publishing team are vital to success. Throughout the project lifecycle, our management team meticulously plans every step, setting clear timelines and responsibilities to ensure steady progress. Our publishing experts, with their profound grasp of eCTD technical standards, carefully prepare and review all documentation, guaranteeing the submission’s quality and compliance. This dedicated, collaborative team is what enables BrilliantMed to stand out in a highly competitive market and deliver superior service to our clients.
4. From Individual Success to Industry Advancement: Setting a New Standard for China’s Submission Capabilities
This milestone fully demonstrates BrilliantMed’s leadership in the eCTD service arena. Looking ahead, we will continue to advance with professionalism, efficiency, and innovation at our core. We are committed to delivering premium eCTD services to more pharmaceutical companies, pushing boundaries, and reaching new heights. We also look forward to partnering with industry stakeholders to drive innovation in China’s pharmaceutical sector, helping more domestic new drugs enter the global market and ultimately improving patient outcomes worldwide.